Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

NCT00779935 | Completed Phase 4

• 1 other identifier: P04041
• Study Type: interventional
• Target: 44
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase 4, multi-center, open-label, one-arm, pilot study in patients with active ankylosing spondylitis refractory to conventional treatment. Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54. The number of patients showing ASAS-20 clinical response at Week 14 will be evaluated.

Conditions

Spondylitis, Ankylosing

Outcome Measures

Primary Outcomes (1)

• To investigate whether baseline serum VEGF concentration predicts ASAS-20 clinical response to infliximab at Week 14.

  Week 14

Secondary Outcomes (4)

• To detect clinical response rates at Weeks 2, 6, 14, 30, 54, and at Follow-up Visit 2, which is 6 months after completion of study treatment.

  Weeks 2, 6, 14, 30, 54 and 6 months afterwards

• To measure the duration of response

  Weeks 2, 6, 14, 30, 54 and 6 months afterwards

• To detect the percent of patients reaching partial response

  Weeks 2, 6, 14, 30, 54 and 6 months afterwards

• To measure the duration of partial response

  Weeks 2, 6, 14, 30, 54 and 6 months afterwards

Study Arms (1)

Remicade

EXPERIMENTAL

Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.

Biological: Remicade

Interventions

Remicade BIOLOGICAL

Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.

Also known as: Infliximab, SCH 215596

Remicade

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of ankylosing spondylitis proven by appropriate diagnostic methods (according to New York criteria).
• Refractory disease defined by failure of at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) during a 3-month period and failure of sulfasalazine in subjects with associated peripheral arthritis.
• Active disease defined by:
• sustained BASDAI of at least 40 on a 0-100 scale and
• expert opinion based on clinical features.
• Age between 18 and 70 years.
• Subjects using NSAIDs and/or sulfasalazine must have been on a stable dose for at least 4 weeks prior to study initiation, and may continue medication during the treatment period, but the dose must not be increased above the baseline.
• Subjects must be capable to demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
• Men and women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (eg, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (eg, hysterectomy or tubal ligation).
• Subjects must understand and be able to adhere to the dosing and visit schedules.

You may not qualify if:

• Subject with moderate or severe heart failure (NYHA class III/IV).
• Remicade must not be given to subjects with a history of hypersensitivity to infliximab, to other murine proteins, or to any of the excipients.
• Subjects with pre-existing or recent onset of central nervous system demyelinating disorders.
• Age \<18 or \>70 years.
• Pregnant women, nursing mothers.
• Subjects who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
• Subjects who have any current systemic inflammatory condition with signs and symptoms that might confound the evaluations of benefit from infliximab therapy.
• Prior administration of infliximab or any other therapeutic agent targeted at reducing TNF (eg, Etanercept, pentoxifylline, thalidomide or anti-CD4+ antibody).
• Current treatment with systemic corticosteroid.
• Treatment with any investigational drug within the previous 3 months.
• History of known allergies to murine proteins.
• Subjects having active or inactive tuberculosis (TB). All subjects must be evaluated for both active and inactive ('latent') TB. This evaluation should include a detailed medical history with personal history of TB or possible previous contact with TB and previous and/or current immunosuppressive therapy. Appropriate screening tests (ie, tuberculin skin test and chest x-ray) should be performed in all subjects.
• History of opportunistic infections such as herpes zoster within 2 months of study initiation. Evidence of active CMV, active pneumocystis carinii, drug resistant atypical mycobacterium, etc.
• Documented HIV infection.
• Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological, or cerebral disease.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

MeSH Terms

Conditions

Spondylitis, Ankylosing

Interventions

Infliximab

Condition Hierarchy (Ancestors)

Axial Spondyloarthritis; Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Ankylosis; Joint Diseases; Arthritis

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 23, 2008
• First Posted: October 24, 2008
• Study Start: October 1, 2004
• Primary Completion: October 1, 2005
• Study Completion: February 1, 2007
• Last Updated: May 11, 2017

Record last verified: 2017-05